ICU Medical (ICUI)
(Delayed Data from NSDQ)
$178.55 USD
-0.46 (-0.26%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $178.62 +0.07 (0.04%) 6:42 PM ET
3-Hold of 5 3
B Value B Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$178.55 USD
-0.46 (-0.26%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $178.62 +0.07 (0.04%) 6:42 PM ET
3-Hold of 5 3
B Value B Growth B Momentum B VGM
Zacks News
Rely on Driehaus Strategy and Buy These 5 Momentum Stocks
by Zacks Equity Research
Investors with high risk-tolerance can invest in momentum stocks using Driehaus Strategy.
Zacks.com highlights: Stamps.com, ICU Medical, LeMaitre Vascular, United States Cellular and Everest Re Group
by Zacks Equity Research
Zacks.com highlights: Stamps.com, ICU Medical, LeMaitre Vascular, United States Cellular and Everest Re Group
Boost Immunity to Market Volatility With 5 Low-Beta Stocks
by Zacks Equity Research
We have developed a strategy which clearly shows that stocks with low risk could also reward investors with handsome returns.
ICU Medical (ICUI) Hits a 52-Week-High, Can the Run Continue?
by Zacks Equity Research
ICU Medical, Inc. is at a 52-week high, but can investors hope for more gains in the future? We take a look at the fundamentals for ICUI for clues.
Fresenius Medical (FMS) Q4 Earnings Beat, View Impressive
by Nabaparna Bhattacharya
Higher sales of dialyzers, machines, peritoneal dialysis products, renal pharmaceuticals, bloodlines and products for acute care boost Fresenius Medical (FMS) in Q4.
Here's Why You Should Invest in Bio-Rad (BIO) Right Now
by Zacks Equity Research
Positive tidings on the regulatory front and strong fourth-quarter performance boost investors' confidence in Bio-Rad (BIO).
Veeva Systems Rides on Strong Q4 & Cloud-Based Applications
by Zacks Equity Research
Industry expertise and expanding product portfolio in cloud-based solutions to bolster Veeva Systems' (VEEV) prospects.
Cerner Collaborates With Salesforce, Focuses on AI Trends
by Zacks Equity Research
Cerner (CERN) has been in the headlines, courtesy of its consistent efforts to digitize electronic health record systems.
Ecolab Gains From Strength in Global Industrial Segment
by Zacks Equity Research
Ecolab (ECL) witnesses improvement in underlying sales volume and pricing in most business segments.
Will International Expansion Aid JD.com (JD) Q4 Earnings?
by Zacks Equity Research
Strong growth in e-commerce business and international expansion are likely to drive JD.com's fourth-quarter earnings.
MedTech's Long-Term Prospects Outweigh Near-Term Risks
by Mark Vickery
A growing prevalence of minimally invasive surgeries, rising demand for liquid biopsy tests, use of IT for ensuring quick and improved patient care and the shift of the payment system to a value-based model are among the updates.
Product Innovation Drives Illumina, Downbeat Margins a Woe
by Zacks Equity Research
Illumina (ILMN) harbors hopes about recent launches like NovaSeq S4 flow cell and reagent kit for its NovaSeq 6000 System. A low margin scenario due to the NovaSeq launch is a concern.
PRA Health (PRAH) Hits 52-Week High on Multiple Positives
by Zacks Equity Research
PRA Health (PRAH) touches 52-week high on consistent revenue performance and Symphony Health integration.
Zimmer Biomet Suffers a Dull Knee Business & Supply Delay
by Zacks Equity Research
Zimmer Biomet (ZBH) fights challenges like supply delay of certain products that curb its capacity to regain lost US-based customers and net in the new ones.
ICU Medical (ICUI) in Focus: Stock Moves 10.2% Higher
by Zacks Equity Research
ICU Medical (ICUI) saw its shares rise over 10% on the day.
Should You Buy ICU Medical (ICUI) Ahead of Earnings?
by Zacks Equity Research
ICU Medical (ICUI) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
4 Medical Device Stocks to Top Q3 Earnings
by Zacks Equity Research
A look at how medical device players are poised for this earnings season.
Pfizer (PFE) Beats on Q3 Earnings, Raises 2017 EPS View
by Zacks Equity Research
Pfizer (PFE) beat expectations for earnings while delivering in-line revenues in Q3. It raised its adjusted earnings guidance while tightening revenue expectations for 2017.
Pfizer (PFE) Q1 Earnings Beat, Sales Lag, 2017 View Intact
by Zacks Equity Research
Pfizer, Inc. (PFE) reported first-quarter 2017 adjusted earnings per share of 69 cents, which beat the Zacks Consensus Estimate of 67 cents by 3%.
MedTech Stocks' Q4 Earnings on Mar 1: ICUI, GKOS & EGRX
by Zacks Equity Research
Let's take a look at the major MedTech stocks within the broader medical community, slated to release their reports on Mar 1.
Walgreens Teams Up with Fedex to Boost Retail Performance
by Zacks Equity Research
Walgreens Boots Alliance, Inc. (WBA) recently inked a multi-year partnership agreement with global express delivery services company FedEx Corporation (FDX).
Align Poised On Global Expansion & Invisalign Teen Growth
by Zacks Equity Research
On Jan 10, 2017, we issued an updated research report on California-based Align Technology Inc. (ALGN).
Illumina (ILMN) Launches NovaSeq Series for $100 Genome
by Zacks Equity Research
Illumina, Inc. (ILMN) recently unveiled the NovaSeq Series, a scalable sequencing solution expected to enable a $100 genome.
QIAGEN (QGEN) Buys OmicSoft, Expands Bioinformatics Suite
by Zacks Equity Research
QIAGEN N.V. (QGEN) recently announced the acquisition of Cary, NC-based OmicSoft Corporation.
LLabCorp: Reimbursement Scenario a Drag Amid Other Woes
by Zacks Equity Research
On Jan 09, we issued an updated research report on Burlington, NC-based Laboratory Corporation of America Holdings (LH) or LabCorp.